Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and gastroparesis. The study is designed to evaluate the efficacy and safety of multiple dose regimens of RM-131. Study drug (RM-131 and placebo) will be administered subcutaneously in a blinded fashion.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis	Drug: RM-131; Drug: Placebo	Phase 2

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	204 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Study Start Date :	April 2012
Actual Primary Completion Date :	August 2013
Actual Study Completion Date :	September 2013

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: RM-131	Drug: RM-131; Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
Placebo Comparator: Placebo	Drug: Placebo; Placebo given subcutaneously for 35 days

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Effect of RM-131 on gastric emptying time [ Time Frame: Screening and Day 28 ]
   Change from baseline in gastric half-emptying time (t½)

Secondary Outcome Measures :

1. Effect of RM-131 on symptoms of gastroparesis [ Time Frame: Baseline, daily for 28 days, and Day 35 ]
   Longitudinal change from baseline over time in daily symptom scores from a self administered daily symptom diary
2. Safety and tolerability of RM-131 [ Time Frame: From Screening through Day 35 ]
   Assessment of adverse events and clinical laboratory evaluations

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures.
• Type 1 or Type 2 diabetes mellitus with HbA1c ≤11% at screening.
• Diabetic gastroparesis defined as at least 3 months history of symptoms suggestive of gastroparesis on an ongoing basis.
• Average Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) > 2.6 during Visit 2.
• History of nausea and/or vomiting/emesis at least once a week during the 2 weeks prior to Visit 1.
• Delayed gastric emptying confirmed at screening by abnormal gastric emptying breath test (GEBT), defined as half-emptying time (t½) > 79 minutes.
• Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to Visit 2.
• No use of metoclopramide, erythromycin or anti-emetics for at least 2 weeks prior to Visit 2.
• Body mass index > 18 kg/m2.
• Female patients must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female patients unable to bear children must have this documented in the electronic case report form (eCRF) (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by FSH.

Exclusion Criteria:

• Currently receiving parenteral feeding; presence of a nasogastric or other enteral tube for feeding or decompression.
• History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure.
• History of pyloric injection of botulinum toxin within 6 months of screening.
• Persistent daily vomiting.
• Patients with clinical suspicion of upper gastrointestinal obstruction must have been evaluated per standard of care, and obstruction ruled out before screening.
• Currently taking opiates.
• Currently taking GLP-1 and amylin analogs.
• Allergic or intolerant of egg, wheat, milk or algae, as these are components of the GEBT study meal.
• History of anorexia nervosa, binge-eating or bulimia within 5 years.
• ALT or AST > 2 X upper limit of normal during screening.
• History of intestinal malabsorption or pancreatic exocrine disease.
• Requires hemodialysis or has end-stage renal disease.
• History of human immunodeficiency virus (HIV) infection.
• Clinically significant neurologic or psychiatric disorders which are likely to impact compliance with protocol requirements.
• Poor venous access or inability to tolerate venipuncture.
• Participation in a clinical study within the 30 days prior to dosing in the present study.
• Any other reason, which in the opinion of the Investigator, including renal, hepatic or cardiopulmonary disease, or significant acute ECG abnormalities that would confound proper interpretation of the study or expose a patient to unacceptable risk.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

  Show 30 Study Locations

Sponsors and Collaborators

Motus Therapeutics, Inc.

Investigators

Study Director:	Chief Development Officer	Rhythm Pharmaceuticals, Inc.

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, White J, Currie M, Gottesdiener K, Stoner E; RM-131-004 Trial Group. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. Gastroenterology. 2016 Jul;151(1):87-96.e6. doi: 10.1053/j.gastro.2016.03.038. Epub 2016 Apr 4.

Responsible Party:	Motus Therapeutics, Inc.
ClinicalTrials.gov Identifier:	NCT01571297 History of Changes
Other Study ID Numbers:	RM-131-004
First Posted:	April 5, 2012
Last Update Posted:	September 23, 2016
Last Verified:	September 2016

Keywords provided by Motus Therapeutics, Inc.:

Diabetes Mellitus; Delayed Gastric Emptying; Gastroparesis; Gastrointestinal Motility Disorder

Additional relevant MeSH terms:

Diabetes Mellitus; Gastroparesis; Diabetes Complications; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases	Stomach Diseases; Gastrointestinal Diseases; Digestive System Diseases; Paralysis; Neurologic Manifestations; Signs and Symptoms